Talquetamab vs Real-World Physician's Choice in Patients With Relapsed/Refractory Multiple Myeloma and Prior B-Cell Maturation Antigen Therapy: Analyses of MonumenTAL-1 vs LocoMMotion/MoMMent

被引:0
|
作者
Mateos Manteca, Maria-Victoria [1 ]
Jakubowiak, Andrzej [2 ]
Einsele, Hermann [3 ]
Schinke, Carolina [4 ]
Besemer, Britta [5 ]
Anguille, Sebastien [6 ]
Manier, Salomon [7 ]
Rasche, Leo [8 ]
Goldschmidt, Hartmut [9 ]
van de Donk, Niels [10 ,11 ]
Perrot, Aurore [12 ]
Teipel, Raphael [13 ]
Karlin, Lionel [14 ]
Scheid, Christof [15 ]
San-Miguel, Jesus [16 ]
Pawlyn, Charlotte [17 ,18 ]
Martinez-Lopez, Joaquin [19 ]
Cavo, Michele [20 ]
Diels, Joris [21 ]
Renaud, Thomas [22 ]
Orel, Oleksiy [23 ]
Cabrieto, Jedelyn [21 ]
Perualila, Nolen [21 ]
Weisel, Katja [24 ]
Moreau, Philippe [25 ]
机构
[1] Univ Hosp Salamanca, Inst Biomed Res Salamanca IBSAL, CIBERONC, Salamanca, Spain
[2] Univ Chicago, Chicago, IL USA
[3] Univ Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany
[4] Univ Arkansas Med Sci, Myeloma Ctr, Little Rock, AR USA
[5] Univ Tubingen, Tubingen, Germany
[6] Univ Antwerp, Antwerp Univ Hosp, Ctr Cell Therapy & Regenerat Med, Vaccine & Infect Dis Inst, Antwerp, Belgium
[7] Univ Lille, CHU Lille, Lille, France
[8] Univ Hosp Wurzburg, Wurzburg, Germany
[9] Univ Hosp Heidelberg, GMMG Study Grp, Dept Internal Med 5, Heidelberg, Germany
[10] Vrije Univ Amsterdam, Amsterdam Univ Med Ctr, Dept Hematol, Amsterdam, Netherlands
[11] Canc Ctr Amsterdam, Amsterdam, Netherlands
[12] Univ Toulouse, Serv Hematol, Toulouse, France
[13] Tech Univ Dresden, Univ Klinikum Carl Gustav Carus, Med Klin & Poliklin 1, Dresden, Germany
[14] Ctr Hosp Lyon Sud, Lyon, France
[15] Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany
[16] Clin Univ Navarra, Navarra, Spain
[17] Inst Canc Res, London, England
[18] Royal Marsden NHS Fdn Trust, London, England
[19] Univ Complutense Madrid, CNIO Clin Res Unit H12O, CIBERONC, Dept Hematol,Hosp 12 Octubre, Madrid, Spain
[20] Univ Bologna, IRCCS Azienda Osped Univ Bologna, Ist Ematol Seragnoli, Bologna, Italy
[21] Janssen Pharmaceut NV, Beerse, Belgium
[22] Janssen Res & Dev, Raritan, NJ USA
[23] Janssen Cilag GmbH, Neuss, Germany
[24] Univ Med Ctr Hamburg Eppendorf, Hamburg, Germany
[25] Univ Hosp Hotel Dieu, Hematol Dept, Beirut, Lebanon
来源
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
P-050
引用
收藏
页码:S69 / S70
页数:2
相关论文
共 50 条
  • [1] Updated Comparative Effectiveness of Talquetamab vs Real-World Physician's Choice of Treatment in LocoMMotion and MoMMent for Patients With Triple-Class Exposed Relapsed/ Refractory Multiple Myeloma
    Einsele, Hermann
    Moreau, Philippe
    Bahlis, Nizar J.
    Bhutani, Manisha
    Vincent, Laure
    Karlin, Lionel
    Perrot, Aurore
    Goldschmidt, Hartmut
    van de Donk, Niels
    Ocio, Enrique
    Martinez-Lopez, Joaquin
    Rodriguez-Otero, Paula
    Dytfeld, Dominik
    Diels, Joris
    Strulev, Vadim
    Haddad, Imene
    Renaud, Thomas
    Cabrieto, Jedelyn
    Perualila, Nolen
    Ammann, Eric
    Parekh, Trilok
    Albrecht, Claire
    Weisel, Katja
    Mateos Manteca, Maria-Victoria
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S50 - S51
  • [2] Comparative effectiveness of teclistamab vs real-world physician's choice of therapy in the LocoMMotion and MoMMent studies for patients with triple-class exposed relapsed/refractory multiple myeloma
    Mateos, Maria-Victoria
    van de Donk, Niels
    Delforge, Michel
    Einsele, Hermann
    De Stefano, Valerio
    Lindsey-Hill, Joanne
    Vincent, Laure
    Kirkpatrick, Suriya
    Besemer, Britta
    Gonzalez Garcia, Maria Esther
    Karlin, Lionel
    Ghilotti, Francesca
    Diels, Joris
    Morano, Raul
    Albrecht, Claire
    Strulev, Vadim
    Haddad, Imene
    Pei, Lixia
    Kobos, Rachel
    Smit, Jennifer
    Slavcev, Mary
    Marshall, Alexander
    Weisel, Katja
    Moreau, Philippe
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S199 - S199
  • [3] Comparative Effectiveness of Teclistamab Versus Real-World Physician’s Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
    Philippe Moreau
    María-Victoria Mateos
    Maria Esther Gonzalez Garcia
    Hermann Einsele
    Valerio De Stefano
    Lionel Karlin
    Joanne Lindsey-Hill
    Britta Besemer
    Laure Vincent
    Suriya Kirkpatrick
    Michel Delforge
    Aurore Perrot
    Niels W. C. J. van de Donk
    Charlotte Pawlyn
    Salomon Manier
    Xavier Leleu
    Joaquin Martinez-Lopez
    Francesca Ghilotti
    Joris Diels
    Raúl Morano
    Claire Albrecht
    Vadim Strulev
    Imène Haddad
    Lixia Pei
    Rachel Kobos
    Jennifer Smit
    Mary Slavcev
    Alexander Marshall
    Katja Weisel
    Advances in Therapy, 2024, 41 : 696 - 715
  • [4] Comparative Effectiveness of Teclistamab Versus Real-World Physician's Choice of Therapy in LocoMMotion and MoMMent in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
    Moreau, Philippe
    Mateos, Maria-Victoria
    Gonzalez Garcia, Maria Esther
    Einsele, Hermann
    De Stefano, Valerio
    Karlin, Lionel
    Lindsey-Hill, Joanne
    Besemer, Britta
    Vincent, Laure
    Kirkpatrick, Suriya
    Delforge, Michel
    Perrot, Aurore
    van de Donk, Niels W. C. J.
    Pawlyn, Charlotte
    Manier, Salomon
    Leleu, Xavier
    Martinez-Lopez, Joaquin
    Ghilotti, Francesca
    Diels, Joris
    Morano, Raul
    Albrecht, Claire
    Strulev, Vadim
    Haddad, Imene
    Pei, Lixia
    Kobos, Rachel
    Smit, Jennifer
    Slavcev, Mary
    Marshall, Alexander
    Weisel, Katja
    ADVANCES IN THERAPY, 2024, 41 (02) : 686 - 695
  • [5] Updated Comparative Effectiveness of Talquetamab vs Real-world Physician's Choice of Treatment in Patients With Triple-Class Exposed Relapsed/Refractory Multiple Myeloma
    Ye, Jing Christine
    Biran, Noa
    Nair, Sandhya
    Lin, Xiwu
    Qi, Keqin
    Ammann, Eric
    Renaud, Thomas
    Kane, Colleen
    Parekh, Trilok
    Gray, Kathleen
    Zhang, Xinke
    Costa, Luciano
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S99 - S100
  • [6] Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma
    Hermann Einsele
    Philippe Moreau
    Nizar Bahlis
    Manisha Bhutani
    Laure Vincent
    Lionel Karlin
    Aurore Perrot
    Hartmut Goldschmidt
    Niels W. C. J. van de Donk
    Enrique M. Ocio
    Joaquin Martinez-Lopez
    Paula Rodríguez-Otero
    Dominik Dytfeld
    Joris Diels
    Vadim Strulev
    Imene Haddad
    Thomas Renaud
    Eric Ammann
    Jedelyn Cabrieto
    Nolen Perualila
    Ryan Gan
    Youyi Zhang
    Trilok Parekh
    Claire Albrecht
    Katja Weisel
    Maria-Victoria Mateos
    Advances in Therapy, 2024, 41 : 1576 - 1593
  • [7] Talquetamab vs real-world physician′s choice of therapy (RWPC): comparative efficacy in patients (pts) with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM)
    Ye, Jing Christine
    Biran, Noa
    Nair, Sandhya
    Lin, Xiwu
    Qi, Keqin
    Londhe, Anil
    Ammann, Eric
    Renaud, Thomas
    Kane, Colleen
    Parekh, Trilok
    Gray, Kathleen
    Peterson, Steve
    Costa, Luciano
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S219 - S220
  • [8] Comparative Efficacy of Talquetamab vs. Current Treatments in the LocoMMotion and MoMMent Studies in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma
    Einsele, Hermann
    Moreau, Philippe
    Bahlis, Nizar
    Bhutani, Manisha
    Vincent, Laure
    Karlin, Lionel
    Perrot, Aurore
    Goldschmidt, Hartmut
    van de Donk, Niels W. C. J.
    Ocio, Enrique M.
    Martinez-Lopez, Joaquin
    Rodriguez-Otero, Paula
    Dytfeld, Dominik
    Diels, Joris
    Strulev, Vadim
    Haddad, Imene
    Renaud, Thomas
    Ammann, Eric
    Cabrieto, Jedelyn
    Perualila, Nolen
    Gan, Ryan
    Zhang, Youyi
    Parekh, Trilok
    Albrecht, Claire
    Weisel, Katja
    Mateos, Maria-Victoria
    ADVANCES IN THERAPY, 2024, 41 (04) : 1576 - 1593
  • [9] Teclistamab and talquetamab modulate levels of soluble B-cell maturation antigen in patients with relapsed and/or refractory multiple myeloma.
    Girgis, Suzette
    Xin, Shun
    Lin, Wang
    Pillarisetti, Kodandaram
    Verona, Raluca
    Vieyra, Diego
    Casneuf, Tineke
    Fink, Damien
    Miao, Xin
    Chen, Yang
    Stephenson, Tara
    Banerjee, Arnob
    Hilder, Brandi
    Russell, Jeffery Scott
    Smit, Jennifer
    Goldberg, Jenna D.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [10] B-cell maturation antigen-based therapies post-talquetamab in relapsed or refractory multiple myeloma
    Shrestha, Asis
    Alzubi, Marah
    Alrawabdeh, Jawad
    Schinke, Carolina
    Thanendrarajan, Sharmilan
    Zangari, Maurizio
    van Rhee, Frits
    Al Hadidi, Samer
    EJHAEM, 2024, 5 (03): : 554 - 559